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Insulinoma is an exceedingly uncommon pancreatic islet cell neuroendocrine tumor. The estimated incidence
is approximately four cases per million individuals per year and accounts for 60% of islets cell tumors.
It causes glycopenic symptoms which includes headache, feeling irritable, confused, seizure or coma and leads
to catecholamine excess which includes rapid heartbeat, sweating, palpitations and feelings of hunger. Early
detection of the tumor prevents recurrent episodes of lethal hypoglycemia.
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O
ur patient is a 22-year-old female college stu-
dent whose only past medical history includes
2 years of recurrent hypoglycemia episodes.
She does not take any prescription medications or over-
the-counter supplements. Her social history includes
drinking one to two beers on the weekends. She lives
alone, works at a local restaurant, and none of her fam-
ily members have a history of diabetes mellitus or any
cancer.
Her first episode of hypoglycemia occurred in October
2012. She was found in her car, after she had run off the
road and was stopped by a bush. Her air bags did not
deploy, and emergency medical services personnel broke
open her car window to reach her. She was awake but
unable to follow commands. She was found to have stable
vital signs with a heart rate of 120 beats/min and blood
glucose level of 35 mg/dl which increased with intrave-
nous dextrose and glucagon injection. She attributed her
symptoms to fasting overnight and skipping breakfast in
the morning. She refused hospitalization at that time.
She subsequently experienced further hypoglycemic
events in January 2013 during a volleyball tournament,
in April 2013 while at a wedding, and in May 2013 while
on a cruise. Her last episode resulted in a generalized
tonic-clonic seizure. All of the episodes resulted in the
rescue squad being called, and she was found to be
hypoglycemic each time. All resulted in recovery with
intravenous dextrose and glucagon injection.
She was eventually admitted the hospital for a 72-h
fasting blood glucose evaluation. During the first 12 h,
her blood glucose dropped to 35 mg/dl, with associated
drowsiness and confusion and responded to IV dextrose.
Laboratory serum studies demonstrated increased proin-
sulin 73.6 pmol/L, insulin 23 uIU/ml, C peptide level 1.93
ng/ml, and beta hydroxybutyrate 0.0 mmol/L (B0.6
mmol/L). Her serum sulfonylurea screen was negative,
and insulin antibody titer was normal at 0.3 U/ml.
She had an abdominal MRI which revealed a 1.71.7
cm arterial enhancing mass in the pancreatic head
without any local invasion or metastases.
She was referred to a tertiary care center and had a
Whipple procedure, was performedwithout complication.
The pathology report showed well differentiated insu-
linoma with no local or distant metastases. She remained
asymptomatic with no recurrent symptoms for the next
6monthsandherrepeatMRIoftheabdomenwasnegative
for residual tumor.
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Insulinoma is an uncommon neuroendocrine pancreatic
tumor. The incidence of insulinoma peaks at 3060 years
of age and is more frequent in women (1, 2). Its estimated
incidence is approximately four cases per million indivi-
dualsperyear(1).Insulinomaaregenerallysmall(B2cm)
and usually not multiple (90%). Only 515% are malig-
nant, and they almost invariably occur only in the
pancreas, distributed equally in the pancreatic head,
body, and tail (3).
The most common clinical symptoms are due to the
effect of hypoglycemia on the central nervous system
(glycopenic symptoms) and include confusion, headache,
disorientation, seizure (4), visual difficulties, irrational
behavior, and even coma (5). In addition, most patients
have symptoms due to excess catecholamine release
secondary to the hypoglycemia, including sweating, tre-
mor, and palpitations. Characteristically, these attacks are
associated with fasting.
The diagnosis of insulinoma requires the demonstra-
tion of an elevated plasma insulin level at the time of
hypoglycemia. The most reliable test to diagnose insu-
linoma is a 72 hour fasting serum glucose, C-peptide,
proinsulin,andinsulinmeasurementsevery48h.Ifatan y
point the patient becomes symptomatic or glucose levels
are persistently below B2.2 mmol/L (40 mg/dl), the test
should be terminated and repeat samples for the above
studies should be obtained before glucose is given.
Generally 7080% of patients will develop hypoglycemia
during the first 24 h and 98% by 48 h (3).
Surreptitious use of insulin or hypoglycemic agents
may be difficult to distinguish from insulinomas. The
combination of proinsulin levels (normal in exogenous
insulin/hypoglycemic agent users), C-peptide levels (low
in exogenous insulin users), antibodies to insulin (positive
in exogenous insulin users), and measurement of sulfo-
nylurea levels in serum or plasma will allow the correct
diagnosis to be made (3).
Unlike most endocrine pancreatic tumors, the majority
(90%) of insulinoma are benign and solitary, and only
10% are malignant. They are typically cured by simple
enucleation. However, tumors located close to the main
pancreatic duct and large ( 2 cm) tumors may require a
distal pancreatectomy or pancreaticoduodenectomy (6).
Surgical resection is the most definitive and curative
treatment for insulinoma.
Sometimes, the lesions are unresectable or metastasis
to the liver or regional lymph node. In such cases, the
treatment approach is variable depending on the extent of
metastasis and functional status of the patient.
Medical therapy may be considered for the non sur-
gical patient and approach to control hypoglycemia events
by decreasing insulin production or antagonizing insulin
effect at receptor level. Diazoxide is the most com-
monly used oral medication to control hypoglycemia
but it causes side effects includes edema and excessive
hair growth (7).
Octreotide and Lanreotide may be used to control
hypoglycemia. These agents also offer some tumor regres-
sion but are not as effective as surgery (8, 9).
Alternatives to medical therapy include, external beam
radio therapy can produce high rates of symptom pallia-
tion and freedom from local progression in patients who
are not candidates for surgical resection (10, 11). Surgical
resectionoftumorshouldbeconsideredinlimitednumber
of hepatic metastases without excessive local tumor
burden and which have acceptable liver function test (12).
In limited case reports, hepatic artery selective che-
moembolization, which predominate supplies cancer he-
patocytes, is frequently applied as a palliative technique
in patients with symptomatic hepatic metastases who
are not candidates for surgical resection (13, 14). Alter-
native approaches include radiofrequency ablation and
cryoablation and are applicable techniques for smaller
lesions, but their long-term efficacy remains uncertain
(15).
Limited randomized controlled trials, and rare inci-
dence of disease with little literature data available, have
limited systemic chemotherapy approach for metastatic
disease, but well-differentiated pancreatic tumors do
respond to cytotoxic chemotherapy including streptozo-
tocin and doxorubicin, and have a combined biochemical
and radiographic response rate of 69% and a medical
survival of 2.2 years (16).
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up after resection of a malignant insulinoma but they
generally include complete history and physical examina-
tions every 36 months and imaging study for recurrence
of disease.
Conclusion
Insulinoma is an exceedingly uncommon pancreatic
islet cell neuroendocrine tumor. The estimated incidence
is approximately four cases per million individuals per
year. It should be one of the working diagnoses in young
patientswith multiple events of hypoglycemia. Insulinomas
are generally 90% benign tumors with excellent surgical
result and have good long term prognosis.
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